Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINIZIDE vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.
250 mg orally twice daily
2-3 hours (prazosin component); prolonged in heart failure or renal impairment
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Prazosin is extensively metabolized in the liver via O-demethylation and conjugation, primarily by CYP3A4. Polythiazide is not extensively metabolized; it is excreted unchanged in the urine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal: 90% (unchanged drug and metabolites); biliary/fecal: <10%
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
97% (prazosin bound to alpha-1 acid glycoprotein and albumin)
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
0.6 L/kg (prazosin); reflects extensive tissue distribution
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 50-70% (prazosin); first-pass metabolism reduces systemic availability
70-90% (oral); 100% (IV).
Contraindicated in patients with GFR <30 m L/min. For GFR 30-60 m L/min: use with caution, reduce dose by 50%, monitor electrolytes. No adjustment for GFR >60 m L/min.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment necessary. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use due to risk of hepatic encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended for pediatric use due to lack of safety and efficacy data.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate therapy at the lower end of the dosing range (1 capsule daily) due to increased sensitivity to orthostatic hypotension and electrolyte disturbances. Titrate slowly.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
First-dose syncope (orthostatic hypotension) can occur, especially with initial use or dose escalation,Sodium and water depletion may occur with thiazide, leading to hypokalemia, hyponatremia, and hypomagnesemia,May exacerbate renal impairment; monitor renal function,May increase serum uric acid and precipitate gout,May cause hypersensitivity reactions, including anaphylaxis and angioedema
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Anuria,Hypersensitivity to prazosin, polythiazide, or sulfonamide-derived drugs (thiazides),Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-potassium foods (e.g., bananas, oranges) if potassium-sparing diuretics or supplements are used; hydrochlorothiazide can cause hypokalemia so potassium-rich foods may be recommended. Grapefruit juice may increase prazosin levels; avoid.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Prazosin-polythiazide combination. First trimester: Risk category C; limited human data. Second and third trimesters: potential fetal/neonatal effects include hypotension, electrolyte imbalance, and decreased placental perfusion. Avoid use unless clearly needed.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Prazosin: low levels in breast milk; M/P ratio 0.75-1.0. Polythiazide: may suppress lactation; M/P ratio unknown. Use caution, monitor infant for diuretic effects or hypotension.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Increased plasma volume and renal clearance may reduce drug levels; consider monitoring therapeutic effect and adjust dose accordingly. No fixed dosing guidelines; cautious titration recommended.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
MINIZIDE (prazosin/hydrochlorothiazide) is a fixed-dose combination for hypertension. Prazosin causes first-dose syncope; start with 1 mg at bedtime. Hydrochlorothiazide may cause hypokalemia; monitor potassium. Use cautiously in patients with history of angioedema from ACE inhibitors as prazosin may also cause angioedema.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take first dose at bedtime to avoid fainting.,Rise slowly from sitting or lying to prevent dizziness.,Avoid alcohol as it may worsen side effects.,Report episodes of fainting or rapid heartbeat.,Do not stop abruptly; may cause rebound hypertension.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINIZIDE vs ALDOCLOR-250, answered by our medical review team.
MINIZIDE is a Antihypertensive Combination that works by Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINIZIDE and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINIZIDE is: 1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINIZIDE and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINIZIDE is classified as Category C. Prazosin-polythiazide combination. First trimester: Risk category C; limited human data. Second and third trimesters: potential fetal/neonatal effects include hypotension, electrol. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.